AR123228A1 - Formas en estado sólido de un compuesto orgánico - Google Patents

Formas en estado sólido de un compuesto orgánico

Info

Publication number
AR123228A1
AR123228A1 ARP210102263A ARP210102263A AR123228A1 AR 123228 A1 AR123228 A1 AR 123228A1 AR P210102263 A ARP210102263 A AR P210102263A AR P210102263 A ARP210102263 A AR P210102263A AR 123228 A1 AR123228 A1 AR 123228A1
Authority
AR
Argentina
Prior art keywords
solid state
state forms
organic compound
conditions
forms
Prior art date
Application number
ARP210102263A
Other languages
English (en)
Inventor
Kristopher Depew
Louis Grenier
Benjamin S Lane
Eric Simone
Jacob Paul Sizemore
Lizarraga Jose Luis Rios
Original Assignee
Servier Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Pharmaceuticals Llc filed Critical Servier Pharmaceuticals Llc
Publication of AR123228A1 publication Critical patent/AR123228A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

En el presente documento se proporcionan varias formas en estado sólido, que incluyen sales, así como varias formas cristalinas y amorfas, del Compuesto I, que está representado por la fórmula estructural: de fórmula (1). También se proporcionan composiciones farmacéuticas que comprenden estos materiales, métodos para su fabricación, usos de los mismos para tratar afecciones, incluidas, entre otras, afecciones que se beneficiarían de la inhibición de la metionina adenosiltransferasa 2a (MAT2A).
ARP210102263A 2020-08-12 2021-08-12 Formas en estado sólido de un compuesto orgánico AR123228A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063064866P 2020-08-12 2020-08-12

Publications (1)

Publication Number Publication Date
AR123228A1 true AR123228A1 (es) 2022-11-09

Family

ID=77693586

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102263A AR123228A1 (es) 2020-08-12 2021-08-12 Formas en estado sólido de un compuesto orgánico

Country Status (3)

Country Link
AR (1) AR123228A1 (es)
TW (1) TW202227446A (es)
WO (1) WO2022036033A2 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69637441T2 (de) * 1995-10-17 2009-03-05 Jagotec Ag Verabreichung unlöslicher arzneistoffe
PL3116491T3 (pl) 2014-03-14 2022-02-07 Les Laboratoires Servier Kompozycje farmaceutyczne związków terapeutycznie aktywnych
AU2017319500C1 (en) 2016-08-31 2022-10-20 Les Laboratoires Servier Inhibitors of cellular metabolic processes
WO2018039972A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
KR20200095480A (ko) 2017-11-02 2020-08-10 아지오스 파마슈티컬스 아이엔씨. 공결정, 그의 제약 조성물, 및 그를 포함하는 치료 방법

Also Published As

Publication number Publication date
WO2022036033A4 (en) 2022-06-23
WO2022036033A3 (en) 2022-04-21
WO2022036033A2 (en) 2022-02-17
TW202227446A (zh) 2022-07-16

Similar Documents

Publication Publication Date Title
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
DOP2021000234A (es) Pirroles triciclicos condensados como moduladores de alfa-1 antitripsina
CL2019000986A1 (es) 1,3 di sustituto ciclobutano o derivados de azetidina como inhibidores de prostaglandina d sintasa hematopoyética(h-pgds).
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
CO6341623A2 (es) Compuestos organicos
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
CL2021000844A1 (es) Compuestos de indolinona para uso como inhibidores de map4k1
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
UY37378A (es) Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus
CL2017002745A1 (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
PE20171348A1 (es) Compuestos de benzoxaborol 4-sustituidos y uso de los mismos
CO2022010547A2 (es) Compuestos y usos de los mismos
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
CL2021002946A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CL2023002633A1 (es) Derivados de uracilo como inhibidores de trpa1
AR121483A1 (es) Hidrato cristalino de un compuesto inhibidor de jak
AR117844A1 (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina
AR127470A1 (es) Inhibidores de lrrk2
CL2021001640A1 (es) Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo
CL2020003248A1 (es) Derivados de tetrahidrotienopiridina n-sustituidos y sus usos
AR123228A1 (es) Formas en estado sólido de un compuesto orgánico

Legal Events

Date Code Title Description
FB Suspension of granting procedure